Ix Biopharma Sustainability Profile
Ix Biopharma Ltd, headquartered in Singapore (SG), is a pioneering biopharmaceutical company specialising in the development of innovative drug delivery systems. Founded in 2008, Ix Biopharma has made significant strides in the industry, particularly with its proprietary WaferiX™ technology, which enhances the delivery of therapeutics through sublingual administration. The company focuses on pain management and other therapeutic areas, offering unique products that provide rapid onset and improved bioavailability. With a strong commitment to research and development, Ix Biopharma has positioned itself as a leader in the biopharmaceutical sector, achieving notable milestones in product development and regulatory approvals. Its dedication to advancing patient care through innovative solutions underscores its reputation as a key player in the global biopharmaceutical landscape.
DitchCarbon Score
How does Ix Biopharma's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Ix Biopharma's score of 20 is lower than 85% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Ix Biopharma's reported carbon emissions
In 2025, Ix Biopharma reported Scope 2 emissions of approximately 1,026,000 kg CO2e in Australia. This figure represents a slight increase from the previous year's emissions of about 949,000 kg CO2e, also under Scope 2, indicating a need for enhanced sustainability measures. The company's global Scope 2 emissions for 2024 were consistent at approximately 949,000 kg CO2e, while in 2023, they were slightly lower at about 937,000 kg CO2e. The emissions for 2022 were recorded at approximately 714,000 kg CO2e, and in 2021, they were about 997,000 kg CO2e. Despite these figures, Ix Biopharma has not set specific reduction targets or initiatives, nor do they participate in recognised climate pledges such as the Science Based Targets initiative (SBTi). The absence of a structured climate commitment suggests that the company may need to develop a more robust strategy to address its carbon footprint and align with industry standards for sustainability. Overall, while Ix Biopharma has made some progress in tracking its emissions, the lack of defined reduction targets highlights an opportunity for improvement in their climate commitments.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|
| Scope 1 | - | - | - | - |
| Scope 2 | 997,000 | 000,000 | 000,000 | 000,000 |
| Scope 3 | - | - | - | - |
How Carbon Intensive is Ix Biopharma's Industry?
How Carbon Intensive is Ix Biopharma's Location?
Ix Biopharma's Climate Goals (2030 & 2050)
Climate goals typically focus on 2030 interim targets and 2050 net-zero commitments, aligned with global frameworks like the Paris Agreement and Science Based Targets initiative (SBTi) to ensure alignment with global climate goals.
Ix Biopharma has not publicly committed to specific 2030 or 2050 climate goals through the major frameworks we track. Companies often set interim 2030 targets and long-term 2050 net-zero goals to demonstrate measurable progress toward decarbonization.
